Recent TNGX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 11:21:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:14:59 AM
- Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights • Business Wire • 05/08/2024 11:00:00 AM
- Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/01/2024 08:48:00 PM
- Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights • Business Wire • 03/18/2024 11:00:00 AM
- Tango Therapeutics to Participate in Upcoming Investor Conferences • Business Wire • 03/06/2024 12:00:00 PM
- Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/05/2024 09:47:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 02:09:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 02:04:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 12:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:22:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:19:40 PM
- Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 01/31/2024 12:00:00 PM
- Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/05/2024 09:05:00 PM
- Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study • PR Newswire (US) • 01/04/2024 07:47:00 AM
- Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting • GlobeNewswire Inc. • 11/13/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 12:29:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 12:07:56 PM
- Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights • GlobeNewswire Inc. • 11/08/2023 12:00:00 PM
- Tango Therapeutics to Present at the Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/07/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 08:49:54 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/18/2023 09:23:38 PM
- Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics • GlobeNewswire Inc. • 09/18/2023 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/12/2023 04:15:28 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONG • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM